EDITOR-IN-CHIEF
DEPUTY EDITOR
The role of vitamin D in breast cancer risk and progression
Authors: Justine Vanhevel et al., Volume 29: Issue 2, Pages: R33–R55
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review
Authors: Mirela Diana Ilie et al., Volume 29: Issue 7, Pages: 415–426
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives
Authors: Olga Karapanou et al., Volume 29: Issue 5, Pages: R57–R66
Androgen receptor mutations for precision medicine in prostate cancer
Authors: Masaki Shiota, Volume 29: Issue 10, Pages: R143–R155
Improved pasireotide response in USP8 mutant corticotroph tumours in vitro
Authors: Adriana Albani et al., Volume 29: Issue 8, Pages: 503–511
Translating the immune microenvironment of thyroid cancer into clinical practice
Authors: Lucas Leite Cunha and Laura Sterian Ward, Volume 29: Issue 6, Pages: R67–R83
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine
Authors: Susan Richter et al., Volume 29: Issue 4, Pages: 213–224
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial
Authors: Cindy H Chau et al., Volume 29: Issue 2, Pages: 99–109
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline
Authors: Sasha R Howard et al., Volume 29: Issue 11, Pages: G1–G33
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures
Authors: Katharina Wang et al., Volume 29: Issue 6, Pages: 285–306
Read our Editor’s favourite articles published in 2022, chosen for their compelling content, originality and quality.
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Authors: Andreas Venizelos et al., Volume 29: Issue 1, Pages: 1–14
Inhibition of GATA2 in prostate cancer by a clinically available small molecule
Authors: Salma Kaochar et al., Volume 29: Issue 1, Pages: 15–31
Improved pasireotide response in USP8 mutant corticotroph tumours in vitro
Authors: Adriana Albani et al., Volume 29: Issue 8, Pages: 503–511
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway
Authors: Chi-Yu Kuo et al., Volume 29: Issue 2, Pages: 47–58
Preclinical evaluation of targeted therapies in Sdhb-mutated tumors
Authors: Sophie Moog et al., Volume 29: Issue 6, Pages: R33–R55
Exploring stem cell biology in pituitary tumors and derived organoids
Authors: Charlotte Nys et al., Volume 29: Issue 2, Pages: R33–R55
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors
Authors: Olga Lakiza et al., Volume 29: Issue 2, Pages: 375–388
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations
Authors: Esra Karslioglu French et al., Volume 29: Issue 8, Pages: 467–473
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings
Authors: Daniela Regazzo et al., Volume 29: Issue 5, Pages: 273–284
The effects of exercise and diet on sex steroids in breast cancer survivors
Authors: Justin C Brown et al., Volume 29: Issue 8, Pages: 485–493
Association of DNA methylation with steroidogenic enzymes in Cushing's adenoma
Authors: Takaya Kodama et al., Volume 29: Issue 8, Pages: 495–502
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors
Authors: Ana Carolina Bueno et al., Volume 29: Issue 11, Pages: 599–613